276 related articles for article (PubMed ID: 30068796)
1. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction.
Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT
Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796
[TBL] [Abstract][Full Text] [Related]
2. Using phage-assisted continuous evolution (PACE) to evolve human PD1.
Ye X; Tu M; Piao M; Yang L; Zhou Z; Li Z; Lin M; Yang Z; Zuo Z
Exp Cell Res; 2020 Nov; 396(1):112244. PubMed ID: 32860814
[TBL] [Abstract][Full Text] [Related]
3. [Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].
Guilleminault L; Carmier D; Heuzé-Vourc'h N; Diot P; Pichon E
Rev Pneumol Clin; 2015 Feb; 71(1):44-56. PubMed ID: 25687821
[TBL] [Abstract][Full Text] [Related]
4. A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).
Shaabani S; Huizinga HPS; Butera R; Kouchi A; Guzik K; Magiera-Mularz K; Holak TA; Dömling A
Expert Opin Ther Pat; 2018 Sep; 28(9):665-678. PubMed ID: 30107136
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients.
Guo L; Bodo J; Durkin L; Hsi ED
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):101-106. PubMed ID: 29084057
[TBL] [Abstract][Full Text] [Related]
6. Exploring the conformational dynamics of PD1 in complex with different ligands: What we can learn for designing novel PD1 signaling blockers?
Ponce LF; García-Martínez K; León K; Valiente PA
Proteins; 2021 Feb; 89(2):141-148. PubMed ID: 32862461
[TBL] [Abstract][Full Text] [Related]
7. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy.
Basher F; Dhar P; Wang X; Wainwright DA; Zhang B; Sosman J; Ji Z; Wu JD
J Hematol Oncol; 2020 Jun; 13(1):74. PubMed ID: 32517713
[TBL] [Abstract][Full Text] [Related]
8. Nanobody against PDL1.
Li S; Jiang K; Wang T; Zhang W; Shi M; Chen B; Hua Z
Biotechnol Lett; 2020 May; 42(5):727-736. PubMed ID: 32006351
[TBL] [Abstract][Full Text] [Related]
9. A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).
Kong X; Lu P; Liu C; Guo Y; Yang Y; Peng Y; Wang F; Bo Z; Dou X; Shi H; Meng J
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760188
[TBL] [Abstract][Full Text] [Related]
10. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
Moon EK; Langer CJ; Albelda SM
Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
[TBL] [Abstract][Full Text] [Related]
11. Recognition of PDL1/L2 by different induced-fit mechanisms of PD1: a comparative study of molecular dynamics simulations.
Lyu N; Wang K; Zhang F; Qin H; Zhao Y; Wu R; Si Y; Wang L
Phys Chem Chem Phys; 2020 Jan; 22(3):1276-1287. PubMed ID: 31850422
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD1/PDL1 induced psoriasis.
Voudouri D; Nikolaou V; Laschos K; Charpidou A; Soupos N; Triantafyllopoulou I; Panoutsopoulou I; Aravantinos G; Syrigos K; Stratigos A
Curr Probl Cancer; 2017; 41(6):407-412. PubMed ID: 29096940
[TBL] [Abstract][Full Text] [Related]
13. PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors.
Chen H; Liu H; Ai J; Du X; Sun Y; Xiao S
Clin Transl Oncol; 2022 Mar; 24(3):586-596. PubMed ID: 34741725
[TBL] [Abstract][Full Text] [Related]
14. MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1.
Li H; Li CW; Li X; Ding Q; Guo L; Liu S; Liu C; Lai CC; Hsu JM; Dong Q; Xia W; Hsu JL; Yamaguchi H; Du Y; Lai YJ; Sun X; Koller PB; Ye Q; Hung MC
Gastroenterology; 2019 May; 156(6):1849-1861.e13. PubMed ID: 30711629
[TBL] [Abstract][Full Text] [Related]
15. Machine-Learning Guided Discovery of Bioactive Inhibitors of PD1-PDL1 Interaction.
Patil SP; Fattakhova E; Hofer J; Oravic M; Bender A; Brearey J; Parker D; Radnoff M; Smith Z
Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631439
[TBL] [Abstract][Full Text] [Related]
16. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer.
Ma YF; Chen C; Li D; Liu M; Lv ZW; Ji Y; Xu J
Oncotarget; 2017 Jan; 8(5):7614-7624. PubMed ID: 27935862
[TBL] [Abstract][Full Text] [Related]
17. Exploiting the Innate Plasticity of the Programmed Cell Death-1 (PD1) Receptor to Design Pembrolizumab H3 Loop Mimics.
Richaud AD; Zaghouani M; Zhao G; Wangpaichitr M; Savaraj N; Roche SP
Chembiochem; 2022 Nov; 23(21):e202200449. PubMed ID: 36082509
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of PD‑L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300‑mediated NF‑κB signaling.
Lucas J; Hsieh TC; Halicka HD; Darzynkiewicz Z; Wu JM
Int J Oncol; 2018 Oct; 53(4):1469-1480. PubMed ID: 30066852
[TBL] [Abstract][Full Text] [Related]
19. Bispecific Aptamer-Based Recognition-then-Conjugation Strategy for PD1/PDL1 Axis Blockade and Enhanced Immunotherapy.
Sun Y; Mo L; Hu X; Yu D; Xie S; Li J; Zhao Z; Fang X; Ye M; Qiu L; Tan W; Yang Y
ACS Nano; 2022 Dec; 16(12):21129-21138. PubMed ID: 36484532
[TBL] [Abstract][Full Text] [Related]
20. PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review).
Li CJ; Lin LT; Hou MF; Chu PY
Oncol Rep; 2021 Jan; 45(1):5-12. PubMed ID: 33416128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
